An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

Ternant, David; Cézé, Nicolas; Lecomte, Thierry; Degenne, Danielle; Duveau, Anne-Claire; Watier, Hervé; Dorval, Étienne; Paintaud, Gilles

doi:10.1097/ftd.0b013e3181ef582a

Cited by 35 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These values are similar to those previously reported in cancer patients. 16,17 The decrease in cardiac index and improvement of epistaxis at 3 and 6 months were not related to bevacizumab exposure as estimated by its cumulated AUC.…”

Section: Bevacizumab Pharmacokineticsmentioning

confidence: 97%

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Dupuis‐Girod

Ginon²,

Saurin³

et al. 2012

JAMA

Self Cite

324

248

View full text Add to dashboard Cite

EREDITARY HEMORRHAGIC telangiectasia (HHT) (Online Mendelian Inheritance in Man [OMIM] #187300) is a dominantly inherited genetic vascular disorder characterized by recurrent epistaxis; cutaneous telangiectasia; and visceral arteriovenous malformations (AVMs) that affect many organs, including the lungs, gastrointestinal tract, liver, and brain. Diagnosis is based on the Curaçao criteria and is considered definite if at least 3 of 4 criteria are fulfilled. 1 The criteria are spontaneous and recurrent epistaxis, Author Affiliations are listed at the end of this article.

show abstract

Section: Bevacizumab Pharmacokineticsmentioning

confidence: 97%

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Dupuis‐Girod

Ginon²,

Saurin³

et al. 2012

JAMA

Self Cite

324

248

View full text Add to dashboard Cite

show abstract

“…10 The detection limit of the ELISA technique used to measure bevacizumab serum concentrations was 0.033 mg/L. 17 Bevacizumab was used without dilution and it has been shown that the drug is very stable, even after storage, making possible use in a nasal spray. 24 However, the nasal mucosa of HHT patients is very often damaged and we can hypothesize that nose bleeds, nasal crusts and dry nose modified local absorption of bevacizumab in HHT patients.…”

Section: Discussionmentioning

confidence: 99%

“…Bevacizumab serum concentrations were measured using a validated ELISA technique. 17 The limit of quantification of this method was 0.033 mg/L.…”

Section: Outcome Measuresmentioning

confidence: 99%

ELLIPSE Study

Dupuis‐Girod

Ambrun

Decullier

et al. 2014

mAbs

Self Cite

View full text Add to dashboard Cite

“…Plasma bevacizumab concentration was quantified by enzyme linked immunosorbent assay (Elisa, Theradiag, Croissy Beaubourg, France) [9]. This method uses biotinylated recombinant human VEGF conjugated to an anti-Human IgG (γ-chain specific), F(ab')2 fragmentPeroxidase antibody and absorbance was measured at 450 nm.…”

Section: Methodsmentioning

confidence: 99%

Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients

B¹,

C²

2015

J Integr Oncol

View full text Add to dashboard Cite

Purpose: Predictive marker of bevacizumab activity is an unmet medical need. Our objective was to evaluate the trough concentration of bevacizumab in patients with recurrent glioblastoma and to analyze its potential association with patient characteristics and outcome. Methods:We retrospectively included patients with recurrent glioblastoma treated with bevacizumab and chemotherapy with available plasma collected before the second bevacizumab administration (residual time). Trough bevacizumab concentrations and antibodies against bevacizumab were quantified by enzyme linked immunosorbent assay (ELISA). Results:We included 21 patients with a median age of 63.4 years at bevacizumab initiation. Occurrence of antibody against bevacizumab was not observed. Median pre-cycle 2 trough concentration of bevacizumab was 87.1 µg/mL (range, 21.7 µg/mL -151.8 µg/mL). Trough concentration of bevacizumab was not correlated to patient age (p=.529), gender (p=.622), weight (p=.403), size (p=.871), Body Mass Index (p=.439), Karnofsky Performans Status (p=.988) and steroid intake (p=0.403). No correlation was found between trough bevacizumab concentration and response rate (p=.856). The highest tertile of trough bevacizumab concentration tended to be associated with poor progression-free survival (p=0.152), while no correlation was observed for overall survival. Conclusion:Evaluation of the trough concentration of bevacizumab during treatment for patients with glioblastoma is feasible and highly variable. Its prognostic value should be explored in prospective trial.

show abstract

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

Abstract: This method is rapid, accurate, reproducible, and may be useful for pharmacokinetic and pharmacokinetic-pharmacodynamic studies as well as in therapeutic drug monitoring of bevacizumab.

Cited by 35 publications

References 16 publications

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

ELLIPSE Study

Bevacizumab Trough Concentration in Recurrent Glioblastoma Patients

Contact Info

Product

Resources

About